PL2976089T3 - Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia - Google Patents

Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia

Info

Publication number
PL2976089T3
PL2976089T3 PL14711754.3T PL14711754T PL2976089T3 PL 2976089 T3 PL2976089 T3 PL 2976089T3 PL 14711754 T PL14711754 T PL 14711754T PL 2976089 T3 PL2976089 T3 PL 2976089T3
Authority
PL
Poland
Prior art keywords
sedoheptulose
inflammation
prevention
treatment
Prior art date
Application number
PL14711754.3T
Other languages
English (en)
Inventor
Arvand Haschemi
Oswald WAGNER
Csörsz Nagy
Rodrig Marculescu
Original Assignee
C7 Sugar Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C7 Sugar Gmbh filed Critical C7 Sugar Gmbh
Publication of PL2976089T3 publication Critical patent/PL2976089T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
PL14711754.3T 2013-03-21 2014-03-21 Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia PL2976089T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160443.1A EP2781219A1 (en) 2013-03-21 2013-03-21 Use of sedoheptulose for prevention or treatment of inflammation
PCT/EP2014/055679 WO2014147214A1 (en) 2013-03-21 2014-03-21 Use of sedoheptulose for prevention or treatment of inflammation

Publications (1)

Publication Number Publication Date
PL2976089T3 true PL2976089T3 (pl) 2023-01-30

Family

ID=47901873

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14711754.3T PL2976089T3 (pl) 2013-03-21 2014-03-21 Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia

Country Status (16)

Country Link
US (2) US9694026B2 (pl)
EP (2) EP2781219A1 (pl)
JP (1) JP6388635B2 (pl)
CN (2) CN105283188A (pl)
AU (1) AU2014234230B2 (pl)
BR (1) BR112015023463A2 (pl)
CA (1) CA2903151C (pl)
DK (1) DK2976089T3 (pl)
ES (1) ES2930249T3 (pl)
HU (1) HUE060237T2 (pl)
MX (1) MX385322B (pl)
NZ (1) NZ711523A (pl)
PL (1) PL2976089T3 (pl)
PT (1) PT2976089T (pl)
WO (1) WO2014147214A1 (pl)
ZA (1) ZA201506396B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement
CN106309458A (zh) * 2016-07-28 2017-01-11 中南大学湘雅医院 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用
CN116602363B (zh) * 2023-06-17 2025-01-24 广东驱动力生物科技集团股份有限公司 一种治疗或预防肉食性鱼脂肪肝的助剂及其制备方法
CN119405681B (zh) * 2024-11-04 2025-09-23 新乡医学院 核糖-5磷酸在制备治疗炎症性疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78166T1 (de) * 1985-10-22 1992-08-15 Silvetti Anthony N Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
JPH04335877A (ja) 1991-05-13 1992-11-24 Eimu:Kk 十薬食品・飲料並びに製造法
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20090252834A1 (en) 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
DE602005019587D1 (de) 2004-07-30 2010-04-08 Vb Medicare Pvt Ltd Süssstoffzusammensetzung mit reduziertem kaloriengehalt
EP1876911A2 (en) 2005-02-28 2008-01-16 McNeil Nutritionals, LLC Brown sugar substitute
JP5048238B2 (ja) * 2005-11-16 2012-10-17 エスエス製薬株式会社 ウワウルシ乾燥エキス含有経口製剤
GB0720516D0 (en) 2007-10-18 2007-11-28 Cadbury Schweppes Plc Comestible products
KR100912277B1 (ko) * 2007-11-21 2009-08-17 한국생명공학연구원 내열성 효소를 이용하여 세도헵툴로스를 제조하는 방법
CN101919872B (zh) * 2010-07-21 2011-12-07 广东粤龙药业有限公司 景酮糖酐在制备抗乙肝药物中的应用
GB201303698D0 (en) 2012-10-26 2013-04-17 Tate & Lyle Ingredients Sweetener syrups
CN103059071B (zh) * 2013-01-08 2016-03-16 华东理工大学 一种单糖的纳滤分离方法
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement

Also Published As

Publication number Publication date
JP2016516077A (ja) 2016-06-02
ZA201506396B (en) 2018-05-30
WO2014147214A1 (en) 2014-09-25
AU2014234230B2 (en) 2018-08-09
MX2015013378A (es) 2016-01-08
MX385322B (es) 2025-03-18
US20160045525A1 (en) 2016-02-18
CA2903151C (en) 2021-11-30
CN115364112A (zh) 2022-11-22
JP6388635B2 (ja) 2018-09-12
AU2014234230A1 (en) 2015-09-17
US9694026B2 (en) 2017-07-04
EP2976089B1 (en) 2022-08-17
ES2930249T3 (es) 2022-12-09
EP2976089A1 (en) 2016-01-27
NZ711523A (en) 2020-09-25
CA2903151A1 (en) 2014-09-25
PT2976089T (pt) 2022-11-22
US10660910B2 (en) 2020-05-26
BR112015023463A2 (pt) 2017-07-18
EP2781219A1 (en) 2014-09-24
DK2976089T3 (da) 2022-11-07
CN105283188A (zh) 2016-01-27
US20170281661A1 (en) 2017-10-05
HUE060237T2 (hu) 2023-02-28

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL273815B (en) Secondary vaccine particles for the treatment of inflammation
IL273090B (en) Methods and preparations for the treatment of cancer
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
EP3620203C0 (en) VASCULAR TREATMENT DEVICES
IL243976A0 (en) kdm1a inhibitors for disease treatment
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
PL4374873T3 (pl) Środek do stosowania w leczeniu lub zapobieganiu schorzeniom okulistycznym
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL251904A0 (en) Apilimod for use in the treatment of melanoma
SG10201705899XA (en) Prevention & treatment of neuropathy
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
ZA201506396B (en) Use of sedoheptulose for prevention or treatment of inflammation
DK2976101T3 (da) Behandlingsfremgangsmåde
DK3041506T3 (da) Behandlingsfremgangsmåde
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201320653D0 (en) Treatment of plants
GB201308665D0 (en) Device for the treatment of bone conditions
GB201319614D0 (en) Fluid treatment
GB201322346D0 (en) Combination treatment of cancer
GB201306411D0 (en) Treatment of inflammatory conditions
TH1501001181A (th) องค์ประกอบสำหรับรักษาโรคสะเก็ดเงิน